Affordable Access

[Current status of castration-resistant prostate cancer translational research].

Authors
  • Maeno, Atsushi
  • Habuchi, Tomonori
Type
Published Article
Journal
Nihon rinsho. Japanese journal of clinical medicine
Publication Date
Jan 01, 2016
Volume
74
Issue
1
Pages
40–44
Identifiers
PMID: 26793877
Source
Medline
License
Unknown

Abstract

Recently, new drugs including abiraterone and enzalutamide have been able to be used for castration resistant prostate cancer(CRPC) patients. However, a subset of these patients who receive the new drugs does not response to the therapies. Furthermore, most patients who initially response to the drugs, progress to secondary resistance eventually. Therefore, it is important to investigate a novel therapeutic target and a novel treatment-selection marker for CRPC. In this review, we focused on AR-V7, TMPRSS2-ERG fusion gene and EP4 antagonist as representative translational researches.

Report this publication

Statistics

Seen <100 times